LEXINGTON, Mass., and CAMBRIDGE, England, March 30 /PRNewswire-FirstCall/ -- Ardais(R) Corporation and Cytomyx Holdings plc announced today a business collaboration under which Cytomyx will acquire the Ardais biorepository of over 130,000 high quality clinically annotated biospecimens. With this transaction, Ardais completes its strategic evolution to a translational medicine solutions provider wholly focused on enabling medical institutions, pharmaceutical and biotechnology companies to collect, manage, process and distribute their own clinically annotated biospecimens through the Ardais System.
"Ardais has been the pioneer and, for many years, the gold standard in providing the highest quality biospecimens for the research community," said Donald B. Hawthorne, President and CEO, Ardais Corporation. "That foundation of experience has enabled us to develop best practices for biospecimen management. The Ardais System is now helping research enterprises to manage their own repositories with proven protocols, software applications, and data standards."
As part of this collaboration, Cytomyx will become a commercial user of the Ardais System, both in its internal operations and in its interactions with customers. Cytomyx will offer comprehensive biological operations services -- including the production of molecular derivatives and pathology verification -- to all former biospecimen customers of Ardais. Medical institutions collecting biospecimens using the Ardais System will also have the opportunity to license excess biospecimens to the research community through Cytomyx. The collaboration is another endorsement of Ardais' strategic move into providing biospecimen management system solutions that address the needs of service providers in addition to academic and commercial entities.
Mike Kerins, Chief Executive Officer of Cytomyx, commented: "We are very pleased to acquire Ardais' biorepository assets, because of the quality and scale of its human tissue biospecimens, its complementary base of pharmaceutical clients, and because of the strategic and operational benefits to Cytomyx. The acquisition builds our strategic position in the high value translational medicine market. Another major benefit of the transaction for us is the opportunity to become a commercial user of the Ardais System technology. This makes management of a complex biospecimen-based business possible on a global basis."
Hawthorne concluded: "This and other recent collaborations are the first steps in pioneering a translational medicine network which will provide infrastructure, support and resources for the growing demand for high quality biospecimens required for successful genomics-based research and clinical development."
Cytomyx will also acquire the lab facilities and lab equipment and will hire Ardais' biological operations personnel. As a result, all former biospecimen customers of Ardais will continue to be able to use the Ardais System in selecting samples and will be served by many of the same employees.
About Ardais Corporation
Ardais Corporation addresses all of the challenges of biospecimen collection, management, and distribution, allowing researchers to focus solely on the research discoveries and clinical developments that will advance translational medicine. As a pioneer in best practices for this field, Ardais has developed the Ardais System, a comprehensive solution that enables academic and commercial scientists and clinicians to standardize their biospecimen collections and efficiently manage their biorepositories, thereby enhancing and accelerating research and clinical development.
The Ardais System, encompassing biological, informatics and engineering expertise, is a suite of software applications, operating procedures, proprietary supplies, and data standards that integrate clients' biorepository operations at one or multiple geographic sites. For more information, visit: http://www.ardais.com/ .
About Cytomyx Holdings plc
Cytomyx Holdings plc is a rapidly growing life science company based in Cambridge, UK. The Company's primary focus is on developing novel technologies that assist pharmaceutical and biotechnology companies in their efforts to develop new treatments more effectively. This it does by providing solutions that provide early insights into the likely efficacy and safety profile of new drugs in development. The Company has two main areas of expertise, the use of human clinical samples in understanding the linkage between gene expression and disease and the development of cell-based assays that are used to predict potential toxicity in new drugs. Cytomyx is listed on the AIM market of the London Stock Exchange (CYX.L). For more information visit http://www.cytomyx-holdings.com/ .
Donald B. Hawthorne
Chief Executive Officer
Chief Executive Officer
Cytomyx Holdings plc
+ 44 (0)1223 508191
Feinstein Kean Healthcare
Ardais Corporation; Cytomyx Holdings plc